| |
 |
| |
 |
Alzheimer’s
Disease (AD), which was first described
about 100 years ago, is today the most
common form of degenerative dementia
thus representing enormous unmet medical,
social and economic needs.
Although it is widely accepted that
protofibrils/plaques comprised of amyloid-b
peptide are causing AD, the underlying
pathomechanism(s) are largely unknown.
Whereas symptomatic treatments are in
use, a Disease-modifying therapy does
not exist yet.
AD
Research
Siena Biotech has developed a balanced
portfolio to tackle this devastating
disorder. An exploratory research program
(ADIT) supported by the VI framework
of the European Commission investigates
the mechanisms by which amyloid-b leads
to neuronal cell death to further the
understanding of how this peptide might
contribute to AD.
A drug discovery project aimed at the
identification of secretase inhibitors
is part of a Disease-modifying program.
Small chemical molecule inhibitors should
reduce amyloid-b levels thus leading
to effective therapy. Two further drug
discovery projects constitute a symptomatic
Disease approach. |
|
|
|
|
|
Alzheimer's Disease